Aspartate-modified doxorubicin on itsN-terminal increases drug accumulation inLAT1-overexpressing tumors

Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood–brain barrier penetration models

(2012) Éva Hellinger et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy

(2012) Kazuhiro Takara et al.   JOURNAL OF CONTROLLED RELEASE

Synthesis of a New pH-Sensitive Folate–Doxorubicin Conjugate and its Antitumor Activity In Vitro

(2012) Wei-Liang Ye et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Pre-Targeting and Direct Immunotargeting of Liposomal Drug Carriers to Ovarian Carcinoma

(2012) Julia Lehtinen et al.   PLoS One

In vitro degradation and antitumor activity of oxime bond-linked daunorubicin–GnRH-III bioconjugates and DNA-binding properties of daunorubicin–amino acid metabolites

(2010) Erika Orbán et al.   AMINO ACIDS

Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells

(2010) Hilary Shmeeda et al.   JOURNAL OF CONTROLLED RELEASE

Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma

(2010) Monica Loi et al.   JOURNAL OF CONTROLLED RELEASE

Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer

(2008) K Kaira et al.   BRITISH JOURNAL OF CANCER

Naringenin Enhances the Anti-Tumor Effect of Doxorubicin Through Selectively Inhibiting the Activity of Multidrug Resistance-Associated Proteins but not P-glycoprotein

(2008) Fa Yun Zhang et al.   PHARMACEUTICAL RESEARCH